Search

Author/Creator Pro, Barbara

1. 90Y‐ibritumomab tiuxetan radiotherapy as first‐line therapy for early stage low‐grade B‐cell lymphomas, including bulky disease. (8th July 2014)

Authors:
Samaniego, Felipe; Berkova, Zuzana; Romaguera, Jorge E.; Fowler, Nathan; Fanale, Michelle A.; Pro, Barbara; Shah, Jatin J.; McLaughlin, Peter; Sehgal, Lalit; Selvaraj, Vijairam; Braun, Frank K.; Mathur, Rohit; Feng, Lei; Neelapu, Sattva S.; Kwak, Larry W.
Journal:
British journal of haematology
Issue:
Volume 167:Number 2(2014:Oct.)
Page Start:
207
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A phase 2 study of epothilone B analog BMS‐247550 (NSC 710428) in patients with relapsed aggressive non‐Hodgkin lymphomas. Issue 9 (10th January 2013)

Authors:
Churpek, Jane E.; Pro, Barbara; van Besien, Koen; Kline, Justin; Conner, Kathy; Wade, James L.; Hagemeister, Fredrick; Karrison, Theodore; Smith, Sonali M.
Journal:
Cancer
Issue:
Volume 119:Issue 9(2013)
Page Start:
1683
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A phase 2 study of epothilone B analog BMS‐247550 (NSC 710428) in patients with relapsed aggressive non‐Hodgkin lymphomas. Issue 9 (10th January 2013)

Authors:
Churpek, Jane E.; Pro, Barbara; van Besien, Koen; Kline, Justin; Conner, Kathy; Wade, James L.; Hagemeister, Fredrick; Karrison, Theodore; Smith, Sonali M.
Journal:
Cancer
Issue:
Volume 119:Issue 9(2013)
Page Start:
1683
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas. Issue 14 (6th December 2021)

Authors:
Pearse, William B.; Petrich, Adam M.; Gordon, Leo I.; Karmali, Reem; Winter, Jane N.; Ma, Shuo; Kaplan, Jason B.; Behdad, Amir; Klein, Andreas; Jovanovic, Borko; Helenowski, Irene; Smith, Sonali M.; Evens, Andrew M.; Pro, Barbara
Journal:
Leukemia & lymphoma
Issue:
Volume 62:Issue 14(2021)
Page Start:
3493
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma (PTCL): final results from the T‐ cell consortium trial. (2nd December 2015)

Authors:
Advani, Ranjana H.; Ansell, Stephen M.; Lechowicz, Mary J.; Beaven, Anne W.; Loberiza, Fausto; Carson, Kenneth R.; Evens, Andrew M.; Foss, Francine; Horwitz, Steven; Pro, Barbara; Pinter‐Brown, Lauren C.; Smith, Sonali M.; Shustov, Andrei R.; Savage, Kerry J.; M. Vose, Julie
Journal:
British journal of haematology
Issue:
Volume 172:Number 4(2016)
Page Start:
535
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. A prospective cohort study of patients with peripheral T‐cell lymphoma in the United States. Issue 7 (2nd December 2016)

Authors:
Carson, Kenneth R.; Horwitz, Steven M.; Pinter‐Brown, Lauren C.; Rosen, Steven T.; Pro, Barbara; Hsi, Eric D.; Federico, Massimo; Gisselbrecht, Christian; Schwartz, Marc; Bellm, Lisa A.; Acosta, Mark A.; Shustov, Andrei R.; Advani, Ranjana H.; Feldman, Tatyana A.; Lechowicz, Mary Jo; Smith, Sonal...
Journal:
Cancer
Issue:
Volume 123:Issue 7(2017)
Page Start:
1174
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Issue 10168 (19th January 2019)

Authors:
Horwitz, Steven; O'Connor, Owen A; Pro, Barbara; Illidge, Tim; Fanale, Michelle; Advani, Ranjana; Bartlett, Nancy L; Christensen, Jacob Haaber; Morschhauser, Franck; Domingo-Domenech, Eva; Rossi, Giuseppe; Kim, Won Seog; Feldman, Tatyana; Lennard, Anne; Belada, David; Illés, Árpád; Tobinai, Kense...
Journal:
Lancet
Issue:
Volume 393:Issue 10168(2019)
Page Start:
229
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma. (9th February 2022)

Authors:
Roy, Ishan; Smilnak, Gordon; Burkart, Madelyn; Hamilton, Elizabeth; Thorp, Katherine; Miyata, Sarah; Ma, Shuo; Pro, Barbara; Winter, Jane; Gordon, Leo; Karmali, Reem
Journal:
British journal of haematology
Issue:
Volume 197:Number 1(2022)
Page Start:
71
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study). (2nd January 2014)

Authors:
Messina, Carlo; Ferreri, Andrés J. M.; Govi, Silvia; Bruno‐Ventre, Marta; Gracia Medina, Elías A.; Porter, David; Radford, John; Heo, Dae S.; Park, Hee Y.; Pro, Barbara; Jayamohan, Jayasingham; Visco, Carlo; Scarfò, Lydia; Zucca, Emanuele; Gospodarowicz, Mary; Christie, David
Journal:
British journal of haematology
Issue:
Volume 164:Number 6(2014:Mar.)
Page Start:
834
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗